These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

950 related items for PubMed ID: 29496056

  • 21. Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
    Zhang WW, Lin JY, Wang GY, Huang CL, Tang LL, Mao YP, Zhou GQ, Liu LZ, Tian L, Li JB, Ma J, Guo R.
    Radiother Oncol; 2024 May; 194():110189. PubMed ID: 38432309
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma.
    Chen KH, Zhu XD, Li L, Qu S, Liang ZQ, Liang X, Pan XB, Liang ZG, Jiang YM.
    Oncotarget; 2016 Oct 18; 7(42):69041-69050. PubMed ID: 27634892
    [Abstract] [Full Text] [Related]

  • 23. Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study.
    Chen TM, Lin KC, Yuan KS, Chang CL, Chow JM, Wu SY.
    Radiother Oncol; 2018 Oct 18; 129(1):23-29. PubMed ID: 29277447
    [Abstract] [Full Text] [Related]

  • 24. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
    Su Z, Mao YP, Tang J, Lan XW, OuYang PY, Xie FY.
    Tumour Biol; 2016 Apr 18; 37(4):4429-38. PubMed ID: 26499947
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years).
    Mi JL, Meng YL, Wu HL, Cao YL, Zhang B, Pan YF, Zhou YY, Fan JF, Liao SF, Qin XL, Yao DC, Jiang W.
    Strahlenther Onkol; 2020 Mar 18; 196(3):270-279. PubMed ID: 31748837
    [Abstract] [Full Text] [Related]

  • 27. The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis.
    Zhong Q, Luo D, Li X, Du Q, Liang Q, Liu W, Li J, Zhu X.
    Cancer Biol Ther; 2023 Dec 31; 24(1):2274121. PubMed ID: 37965924
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H, Chen L, Zhang Y, Guo R, Li WF, Mao YP, Tan LL, Sun Y, Zhang F, Liu LZ, Tian L, Lin AH, Ma J.
    Oncotarget; 2016 Apr 26; 7(17):24208-16. PubMed ID: 27008701
    [Abstract] [Full Text] [Related]

  • 30. The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis.
    Liu F, Jin T, Liu L, Xiang Z, Yan R, Yang H.
    PLoS One; 2018 Apr 26; 13(3):e0194733. PubMed ID: 29566078
    [Abstract] [Full Text] [Related]

  • 31. The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy.
    Miao J, Xiao W, Wang L, Han F, Wu H, Deng X, Guo X, Zhao C.
    J Cancer Res Clin Oncol; 2017 Jul 26; 143(7):1263-1273. PubMed ID: 28247035
    [Abstract] [Full Text] [Related]

  • 32. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ, Mo HY, Luo DH, Hu WH, Jin T.
    Oral Oncol; 2018 Oct 26; 85():95-100. PubMed ID: 30220326
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Zhang J, Chen S, Li G, Zhang W, Qin T, Yin P, Huang H, Jiang H.
    Cancer Chemother Pharmacol; 2017 Jun 26; 79(6):1087-1097. PubMed ID: 28429051
    [Abstract] [Full Text] [Related]

  • 36. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R, Zhu J, Chen X, Liu Y, Wang Y, Zhang T.
    Clin Transl Oncol; 2020 Mar 26; 22(3):429-439. PubMed ID: 31165410
    [Abstract] [Full Text] [Related]

  • 37. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
    Wang C, Tang X, Wang J, Song J, Xu Y.
    Otolaryngol Head Neck Surg; 2017 Aug 26; 157(2):233-238. PubMed ID: 28418781
    [Abstract] [Full Text] [Related]

  • 38. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Tan TH, Soon YY, Cheo T, Ho F, Wong LC, Tey J, Tham IWK.
    Radiother Oncol; 2018 Oct 26; 129(1):10-17. PubMed ID: 29555182
    [Abstract] [Full Text] [Related]

  • 39. Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy.
    Li WF, Li YQ, Chen L, Zhang Y, Guo R, Zhang F, Peng H, Sun Y, Ma J.
    BMC Cancer; 2015 Oct 27; 15():810. PubMed ID: 26506820
    [Abstract] [Full Text] [Related]

  • 40. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
    Liu W, Yu B, Luo Y, Li J, Yuan X, Wu S, Liang B, Lv Z, Li Y, Peng X, Lu J, Peng X, Liu X.
    BMC Cancer; 2021 May 29; 21(1):639. PubMed ID: 34051750
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.